Zentalis Pharmaceuticals Announces First ZN-c3 Clinical Development Collaboration with Pfizer November 2, 2022
Retrospective Analysis of Extended Treatment Benefit from Multiple Trials of Mirvetuximab Soravtansine in Ovarian Cancer presented November 2, 2022
Quizartinib Granted Priority Review in the U.S. for Patients with Newly Diagnosed FLT3-ITD Positive AML November 2, 2022
FDA clears IND for LYL845, a TIL Product Candidate Enhanced with its Novel Epigenetic Reprogramming Technology for Solid Tumors November 2, 2022
BLAs for Epcoritamab (DuoBody®-CD3xCD20) for the Treatment of R/R LBCL and DLBCL submitted November 2, 2022
U.S. FDA Approves TECVAYLI (teclistamab-cqyv) for the Treatment of Patients with R/R Multiple Myeloma November 2, 2022
Imjudo (tremelimumab) in combination with Imfinzi approved in the US for patients with unresectable liver cancer based on Ph 3 HIMALAYA trial November 2, 2022
